| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
185,611,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
6,246,627 |
Avg
Vol: |
2,897,741 |
| 52
Week Range: |
$23.99 - $23.99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2015-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
131,797 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2015-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
114,917 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2015-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,500 |
297,981 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2015-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
127,724 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2015-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,500 |
342,836 |
|
- |
|
| Berstein David L |
SVP, Chief IP Counsel |
• • – |
2015-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
250,449 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2015-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
47,500 |
1,413,992 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2015-09-01 |
4 |
AS |
$9.11 |
$24,557 |
D/D |
(2,696) |
104,917 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2015-08-28 |
4 |
AS |
$10.00 |
$328,580 |
D/D |
(32,858) |
280,481 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2015-08-28 |
4 |
AS |
$10.00 |
$12,680 |
D/D |
(1,268) |
107,613 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2015-07-16 |
4 |
AS |
$8.54 |
$59,797 |
D/D |
(7,000) |
325,336 |
|
- |
|
| Duvall Martin J |
EVP, CCO |
• • – |
2015-07-16 |
4 |
AS |
$8.54 |
$11,956 |
D/D |
(1,400) |
59,748 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2015-07-16 |
4 |
AS |
$8.54 |
$59,793 |
D/D |
(7,000) |
313,339 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2015-07-16 |
4 |
AS |
$8.54 |
$34,164 |
D/D |
(4,000) |
121,797 |
|
- |
|
| Berstein David L |
SVP, Chief IP Counsel |
• • – |
2015-07-16 |
4 |
AS |
$8.54 |
$34,162 |
D/D |
(4,000) |
230,449 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2015-07-16 |
4 |
AS |
$8.54 |
$34,162 |
D/D |
(4,000) |
108,881 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2015-07-16 |
4 |
AS |
$8.54 |
$37,575 |
D/D |
(4,400) |
117,724 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2015-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,000 |
332,336 |
|
- |
|
| Duvall Martin J |
EVP, CCO |
• • – |
2015-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,800 |
61,148 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2015-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,000 |
320,339 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2015-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,000 |
125,797 |
|
- |
|
| Berstein David L |
SVP, Chief IP Counsel |
• • – |
2015-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,000 |
234,449 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2015-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,000 |
112,881 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2015-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,000 |
122,124 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2015-07-15 |
4 |
D |
$8.35 |
$145,040 |
D/D |
(17,370) |
1,366,492 |
|
- |
|
703 Records found
|
|
Page 4 of 29 |
|
|
